GSK has agreed to purchase Nuvalent, a cancer drug developer based in Cambridge, Massachusetts, in a $10.6 billion all-cash transaction. This acquisition represents GSK’s most significant deal in over ten years and positions the British pharmaceutical giant for a more aggressive expansion into oncology.
The offer values Nuvalent at approximately $124 per share, about 40% above its most recent closing price. Central to the deal are two late-stage lung cancer drugs: zidesamtinib (NVL-520) and neladalkib (NVL-655). Both target non-small cell lung cancer through highly selective next-generation inhibition. Zidesamtinib is a ROS1 inhibitor, while neladalkib acts against ALK. These candidates have received FDA Breakthrough Therapy and Orphan Drug designations and are currently under regulatory review, with decision deadlines set for late 2026.
Under the leadership of CEO Luke Miels, GSK has identified oncology as a strategic priority, seeking to increase its market presence and pipeline depth to compete more effectively with rivals. Last year, oncology accounted for about £2.0 billion in revenue, representing 6% of GSK’s group sales. The company projects overall sales exceeding £40 billion annually by 2031.
The acquisition also aligns with GSK’s plan to diversify beyond its HIV portfolio, which faces patent expirations, including a significant one for dolutegravir expected in 2028. Nuvalent’s lung cancer assets offer a new revenue platform that could mitigate anticipated growth challenges in HIV.
Additionally, GSK gains a strategic asset in the antibody-drug conjugate risvutatug rezetecan (Ris-Rez), targeting B7-H3 antigens, which is currently in phase III clinical trials. This reinforces GSK’s ambition to build a robust oncology pipeline with late-stage candidates that may reach the market more rapidly.
Financially, Nuvalent ended 2025 with $1.4 billion in cash and equivalents, sufficient to fund operations into 2029. By acquiring Nuvalent, GSK aims to accelerate the commercial development and launch of these promising therapies rather than following a more prolonged organic path.
This deal ranks as the second largest in GSK’s history, following its $13 billion purchase of Novartis’s stake in their consumer healthcare joint venture in 2018. The size and focus of the acquisition reflect the pharmaceutical industry’s growing emphasis on late-stage oncology franchises as a source of defensible and sustainable growth.